AMAG Pharmaceuticals, Inc. (AMAG) and Palatin Technologies, Inc. (PTN) said Monday that both Phase 3 RECONNECT studies (301, 302) of Rekynda, or bremelanotide, met co-primary end points and demonstrated significant improvement in key symptoms of hypoactive sexual desire disorder.
from RTT - Biotech http://ift.tt/2lqSo9k
via IFTTT
No comments:
Post a Comment